|
Patients, n
|
88
|
84
|
0.666
|
|
Age (y), mean (min./max.)
|
45 (26/64)
|
45 (20/72)
|
0.763
|
|
Sex, male/female (%)
|
66/22 (75/25)
|
52/32 (61/38)
|
0.092
|
|
Genotype, n (%)
| | | |
|
1
|
37/88 (42)
|
49/84 (58)
|
0.033
|
|
2
|
3/88 (3)
|
9/84 (10)
|
0.060
|
|
3
|
25/88 (28)
|
15/84 (17)
|
0.102
|
|
4
|
2/88 (2)
|
5/84 (5)
|
0.222
|
|
Unknwon
|
21/88 (23)
|
6/84 (7)
|
0.003
|
|
Liver biopsy, n (%)
|
17/88 (19)
|
36/84 (42)
|
0.001
|
|
Fibrosis F3 – F4, n (%)
|
6/17 (35)
|
10/36 (27)
|
0.251
|
|
HCV RNA in IU/ml, mean
|
4 714 165
|
3 453 862
|
0.487
|
|
(min./max.)
|
(3/9 × 107)
|
(3/3 × 107)
| |
|
HCV RNA > 800 000, n (%)
|
66/88 (75)
|
32/84 (38)
|
0.001
|
|
HCV RNA < 800 000, n (%)
|
22/88 (25)
|
52/84 (61)
|
0.001
|
|
Alanine transaminase in U/l, mean (min./max.)
|
78 (3/526)
|
105 (15/610)
|
0.098
|
|
Start of heptitis C therapy, n (%)
|
36 (40)
|
52 (61)
|
0.006
|
|
Liver biopsy, n (%)
|
10 (27)
|
27 (51)
|
0.024
|
|
(Fibrosis F3 – F4, n (%)
|
5 (13)
|
8 (29)
|
0.846
|
|
HCV RNA in IU/ml, mean
|
4 799 700
|
3 222 000
|
0.530
|
|
(min./max.)
|
(800/9 × 107)
|
(3/2 × 107)
| |
|
HCV RNA > 800 000, n (%)
|
12 (33)
|
21 (40)
|
0.502
|
|
HCV RNA < 800 000, n (%)
|
24 (66)
|
31 (59)
|
0.502
|
|
Alanine transaminase in U/l, mean (min./max.)
|
94 (29/526)
|
120 (18/610)
|
0.321
|
|
Duration of therapy in weeks, mean (min./max.)
|
33 (1/152)
|
36 (10/128)
|
0.496
|
|
Ribavirin (weight adapted) in mg/week, mean
|
5764,28
|
7567,2
|
0.027
|
|
Peg-Interferon-alfa 2a, n (%)
|
27/36 (75)
|
41/52 (78)
|
0.672
|
|
Peg-Interferon-alfa 2b, n (%)
|
0/36 (0)
|
3/52 (5)
|
0.143
|
|
Non-peg-Interferon, n (%)
|
3/36 (8)
|
0/52 (0)
|
0.034
|
